JP2010011868A5 - - Google Patents

Download PDF

Info

Publication number
JP2010011868A5
JP2010011868A5 JP2009238784A JP2009238784A JP2010011868A5 JP 2010011868 A5 JP2010011868 A5 JP 2010011868A5 JP 2009238784 A JP2009238784 A JP 2009238784A JP 2009238784 A JP2009238784 A JP 2009238784A JP 2010011868 A5 JP2010011868 A5 JP 2010011868A5
Authority
JP
Japan
Prior art keywords
seq
bacteria
immune response
neisseria meningitidis
serosubtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009238784A
Other languages
English (en)
Japanese (ja)
Other versions
JP5215275B2 (ja
JP2010011868A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010011868A publication Critical patent/JP2010011868A/ja
Publication of JP2010011868A5 publication Critical patent/JP2010011868A5/ja
Application granted granted Critical
Publication of JP5215275B2 publication Critical patent/JP5215275B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2009238784A 2001-04-17 2009-10-15 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物 Expired - Fee Related JP5215275B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28455401P 2001-04-17 2001-04-17
US60/284,554 2001-04-17
US32683801P 2001-10-03 2001-10-03
US60/326,838 2001-10-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008074708A Division JP2008259503A (ja) 2001-04-17 2008-03-21 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物

Publications (3)

Publication Number Publication Date
JP2010011868A JP2010011868A (ja) 2010-01-21
JP2010011868A5 true JP2010011868A5 (https=) 2012-01-05
JP5215275B2 JP5215275B2 (ja) 2013-06-19

Family

ID=26962673

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002581466A Withdrawn JP2004529643A (ja) 2001-04-17 2002-04-11 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
JP2008074708A Withdrawn JP2008259503A (ja) 2001-04-17 2008-03-21 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
JP2009238784A Expired - Fee Related JP5215275B2 (ja) 2001-04-17 2009-10-15 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2002581466A Withdrawn JP2004529643A (ja) 2001-04-17 2002-04-11 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
JP2008074708A Withdrawn JP2008259503A (ja) 2001-04-17 2008-03-21 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物

Country Status (10)

Country Link
US (1) US7534444B2 (https=)
EP (1) EP1379272B1 (https=)
JP (3) JP2004529643A (https=)
CN (1) CN1306956C (https=)
AT (1) ATE455793T1 (https=)
AU (1) AU2002252638A1 (https=)
CA (1) CA2439428C (https=)
DE (1) DE60235155D1 (https=)
RU (1) RU2322451C2 (https=)
WO (1) WO2002083711A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP2270173B1 (en) 1999-05-19 2016-01-06 GlaxoSmithKline Biologicals SA Combination neisserial compositions
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
AU2000278267A1 (en) * 2000-09-01 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae o139 conjugate vaccines
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2005023295A2 (en) * 2003-09-10 2005-03-17 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
AU2005214061B2 (en) * 2004-02-18 2010-02-04 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
DE102004023906A1 (de) * 2004-05-13 2005-12-22 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Verfahren zur Herstellung von chemischen Mikroarrays
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
DE112009000608B4 (de) 2008-04-18 2017-12-28 Denso Corporation Kälteerzeugungszyklusvorrichtung eines Ejektor-Typs
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
JP2015517089A (ja) * 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
EP0145359B1 (en) 1983-11-21 1991-01-16 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4970070A (en) 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
US5128460A (en) * 1989-04-04 1992-07-07 Genelabs Incorporated Recombinant trichosanthin and coding sequence
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SU1708846A1 (ru) * 1989-11-22 1992-01-30 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Штамм бактерий NeISSeRIa меNINGIтIDIS серогруппы В - продуцент капсульного полисахарида и полисахаридно-белкового комплекса
DE69019164T2 (de) 1989-12-14 1995-09-07 National Research Council Of Canada, Ottawa, Ontario Verbessertes meningokokkale polysaccharidkonjugatvakzin.
RU2068270C1 (ru) * 1993-01-13 1996-10-27 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Антиген менингококков группы в
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ES2166097T5 (es) 1996-08-27 2007-03-16 Novartis Vaccines And Diagnostics, Inc. Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
US6048527A (en) 1996-08-27 2000-04-11 Chiron Corporation Antibodies that define unique Meningococcal B epitopes and vaccine compositions
CA2301942C (en) 1997-08-27 2011-05-31 Chiron Corporation Molecular mimetics of meningococcal b epitopes
EP2261352A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
JP4812942B2 (ja) 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
JP2003518363A (ja) * 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
CN101033467A (zh) * 1999-04-30 2007-09-12 希龙公司 奈瑟球菌基因组序列及其用法
ES2281409T3 (es) * 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.

Similar Documents

Publication Publication Date Title
JP2010011868A5 (https=)
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
EP2886551A3 (en) Meningococcal fhbp polypeptides
JP2016040284A5 (https=)
JP2012126742A5 (https=)
WO2011024072A3 (en) Hybrid polypeptides including meningococcal fhbp sequences
JP2010166916A5 (https=)
JP2011250797A5 (https=)
JP2008530245A5 (https=)
NZ612315A (en) Compositions for immunising against staphylococcus aureus
WO2008090223A3 (en) Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus
PH12013500453B1 (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
NZ601538A (en) Vaccine compositions comprising a mutated factor h binding protein
HRP20240847T1 (hr) Novi polisaharid i njegove upotrebe
BR112012007876A2 (pt) "membranas de troca de íons"
JP2011510093A5 (ja) 口腔ケア製品ならびにその使用および製造の方法
JP2010534684A5 (https=)
JP2013502918A5 (https=)
JP2010166921A5 (https=)
WO2011008548A8 (en) Vaccines and compositions against streptococcus pneumoniae
JP2009515831A5 (https=)
JP2010532656A5 (https=)
JP2011502165A5 (https=)
WO2012138570A3 (en) Modulating bacterial mam polypeptides in pathogenic disease
JP2013518052A5 (https=)